HK Stock Market Move | Joinn Laboratories (06127) surged over 5%, benefiting from the skyrocketing prices of experimental monkeys. The company's net profit is expected to more than double last year.

Joinn Laboratories (06127) rose more than 5%, as of the deadline, it rose by 5.06%, reaching HK$25.74, with a turnover of HK$1.16 billion. On the news front, recently, Joinn Laboratories announced its annual performance forecast, stating that it is expected to achieve a net profit attributable to shareholders of listed companies of approximately 2.33 billion to 3.49 billion yuan in 2025, an increase of about 214.0% to 371.0% year-on-year. Regarding the reasons for the increase in net profit, Joinn Laboratories pointed out in the announcement that during the reporting period, the rising prices of biological assets combined with the natural growth appreciation of the company itself drove the fair value in a positive direction, making a positive contribution to the company's performance. Specifically, the net profit contributed by the fair value change of biological assets is about 4.52 billion to 5 billion yuan. In January of this year, Yin Hongfei, a senior investment consultant at Yuekai Securities, stated in a media interview that it takes an average of 60 monkeys to consume a new drug from the laboratory to clinical trials, and the dosage for large molecule drugs needs to be doubled. In addition, he mentioned that according to recent market reports and Founder's calculations, the price of a single crab-eating macaque, a core variety, has skyrocketed to 120,000 to 130,000 yuan within a month, with some in short supply already being reported at over 150,000 yuan, an increase of more than 30% compared to two months ago.